This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Cost of Capital at DraftKings
Baker, Malcolm P.; Hillenbrand, Sebastian; Barnett, JamesCase HBS-224007-EFinanceStarting at €8.20
-
Behavioral Finance at JP Morgan
Baker, Malcolm P.; Sesia, AldoCase HBS-207084-EFinanceFollowing a successful model in Europe, JP Morgan has introduced a set of five U.S. retail mutual funds with an investment philosophy and marketing strategy grounded in behavioral finance. The asset management group believes that understanding investor biStarting at €8.20
-
Matrix Capital Management (C)
Baker, Malcolm P.; Lane, DavidCase HBS-211060-EFinanceBen Balbale, a partner at hedge fund Matrix Capital, must decide whether to exit their investment in Rovi Corporation, a company with a diverse portfolio of patents used primarily for digital interactive guides. Rovi's shares are up over 50% from the time Balbale initiated a position in the middle of 2009.Starting at €5.74
-
Restructuring JAL, Teaching Note
Baker, Malcolm P.; Sunderam, AdiTeaching Note HBS-215041-EFinanceTeaching note for 214055.Starting at €0.00
-
Celgene
Baker, Malcolm P.; McComb, Emily R.Case HBS-218094-EFinanceIn February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm's position in Celgene Corporation. News has emerged that raises potential safety concerns associated with Celgene's key drug, Revlimid. In response, Celgene's share price has traded down 20% in the last two months, and is now almost 10% below the level where Brookside made their initial i...Starting at €8.20
-
Multifactor Models
Baker, Malcolm P.Case HBS-207056-EFinanceStudents evaluate the performance of four mutual funds and compute the cost of capital for two companies using fixed benchmarks, the CAPM, and a multifactor model of returns.Starting at €8.20
-
Restructuring at Nova Chemical Corporation Abridged
Baker, Malcolm P.; Mason, Scott P.Case HBS-213075-EFinanceStarting at €8.20
-
Matrix Capital Management (A)
Baker, Malcolm P.; Lane, DavidCase HBS-211017-EFinanceBen Balbale, a partner at hedge fund Matrix Capital, must decide whether to exit their investment in Rovi Corporation, a company with a diverse portfolio of patents used primarily for digital interactive guides. Rovi's shares are up over 50% from the time Balbale initiated a position in the middle of 2009.Starting at €8.20
-
Celgene (B)
Baker, Malcolm P.; McComb, Emily R.Case HBS-218099-EFinanceIn February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm's position in Celgene Corporation. News has emerged that raises potential safety concerns associated with Celgene's key drug, Revlimid. In response, Celgene's share price has traded down 20% in the last two months, and is now almost 10% below the level where Brookside made their initial i...Starting at €5.74
-
Matrix Capital Management (B)
Baker, Malcolm P.; Lane, DavidCase HBS-211048-EFinanceBen Balbale, a partner at hedge fund Matrix Capital, must decide whether to exit their investment in Rovi Corporation, a company with a diverse portfolio of patents used primarily for digital interactive guides. Rovi's shares are up over 50% from the time Balbale initiated a position in the middle of 2009.Starting at €5.74